11th Feb 2015 09:34
LONDON (Alliance News) - Pharmaceutical company Clinigen Group PLC on Wednesday said it has won a contract from FTSE 100-listed drugs company AstraZeneca PLC to manage the global access programme for the CAZ-AVI antibiotic.
CAZ-AVI is being developed to treat a broad range of Gram-negative bacterial infections which are becoming resistant to antibiotics and pose an increasing risk to public health. It is being investigated as a new treatment option for patients with gram-complicated urinary tract infections, complicated intra-abdominal infections and nosocomial pneumonia, Clinigen said.
Under the deal, for which Clinigen did not provide any financial details, Clinigen will handle the access to CAZ-AVI in all countries except the US and Canada via its Clinigen GAP unit.
"I am very pleased to announce the launch of this first program for AstraZeneca, further strengthening the relationship with Clinigen. We now work with AstraZeneca across all our operating businesses. The continued growth within Clinigen GAP demonstrates the increasing need for early access to drugs in areas of critical unmet need," said Clinigen Chief Operating Officer Shaun Chilton.
Clinigen shares were up 0.3% to 514.04 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaCLIN.L